210 related articles for article (PubMed ID: 11366377)
1. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
[TBL] [Abstract][Full Text] [Related]
2. [AIDS triple therapy. The gap between viral load and side effects].
Gürtler L
Fortschr Med; 1998 Sep; 116(27):4-5. PubMed ID: 9816747
[No Abstract] [Full Text] [Related]
3. Drug interactions: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1997; (No 32):4-9. PubMed ID: 11364444
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections.
Konlee M
Posit Health News; 1998; (No 16):2-4. PubMed ID: 11365016
[TBL] [Abstract][Full Text] [Related]
5. Double jeopardy: the hazards of drug-drug interactions.
Flexner C
Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
[TBL] [Abstract][Full Text] [Related]
6. Choosing the right initial antiretroviral regimens.
Norton M
GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions: trials and tribulations.
Crit Path AIDS Proj; 1996; (No 31):4-6. PubMed ID: 11363834
[TBL] [Abstract][Full Text] [Related]
8. AIDS researchers emphasize new drug combinations.
Fox JL
Nat Biotechnol; 1997 Mar; 15(3):215. PubMed ID: 9062914
[No Abstract] [Full Text] [Related]
9. Advances in HIV/AIDS therapy.
Johnson SC; Gerber JG
Adv Intern Med; 2000; 45():1-40. PubMed ID: 10635044
[TBL] [Abstract][Full Text] [Related]
10. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
11. Side effects and combination anti-HIV drugs.
Treat Rev; 1997 Nov; (No 26-27):14-5. PubMed ID: 11364933
[TBL] [Abstract][Full Text] [Related]
12. '96-'97 new drugs and the nominees for 1997 are...
Notes Undergr; 1997; (No 35):suppl 1-2. PubMed ID: 11364566
[TBL] [Abstract][Full Text] [Related]
13. Risks and synergies from drug interactions.
Sahai J
AIDS; 1996 Nov; 10 Suppl 1():S21-5. PubMed ID: 8970672
[TBL] [Abstract][Full Text] [Related]
14. Potential drug interacations.
Posit Aware; 1996; 7(2):14-5. PubMed ID: 11363359
[TBL] [Abstract][Full Text] [Related]
15. New treatment options.
Fornataro K; Jefferys R
Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
[TBL] [Abstract][Full Text] [Related]
16. Managing issues related to antiretroviral therapy.
Lesho EP; Gey DC
Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
[TBL] [Abstract][Full Text] [Related]
17. Targeting a deadly scrap of genetic code.
Cowley G
Newsweek; 1996 Dec; 128(23):68-9. PubMed ID: 10162944
[No Abstract] [Full Text] [Related]
18. [Opportunistic diseases--current aspects in 2004].
Marquardt T; Jablonowski H
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():34-6, 38. PubMed ID: 15373044
[TBL] [Abstract][Full Text] [Related]
19. New anti-HIV drug interactions, toxicities, and dosing options.
Bartnof HS
BETA; 1999; 12(4):60-3, 66. PubMed ID: 11367260
[TBL] [Abstract][Full Text] [Related]
20. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
